Busopin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Busopin

Quick Facts

Property Description
Active ingredient Hyoscine Butylbromide
Form Oral tablets, Solution for injection
Pharmacological class Antispasmodic, Anticholinergic agent
Common use Relieving smooth muscle spasm and cramping
Origin Semisynthetic derivative (of a tropane alkaloid)

What Type of Medicine is Busopin?

Busopin is a medication whose active ingredient is Hyoscine Butylbromide, classified primarily as an antispasmodic agent used to provide relief from painful spasms in the smooth muscles of the body. The drug is clinically recognized for its targeted action and belongs to the broader class of anticholinergics, which work by interfering with the nerve signals that cause involuntary muscle contractions.

The compound itself is a semisynthetic derivative of hyoscine (scopolamine), a naturally occurring tropane alkaloid. Chemically, Hyoscine Butylbromide is defined as a quaternary ammonium compound, a crucial structural feature that limits its systemic effect by minimizing absorption into the central nervous system. This modification ensures that the drug's therapeutic action is concentrated primarily on the muscles lining the gastrointestinal and genitourinary tracts.


What are the Forms and Primary Purpose of Hyoscine Butylbromide?

The medication is commonly supplied in two principal forms: oral tablets for convenience in managing episodes of abdominal cramps, and a solution for injection in ampoules for rapid parenteral administration when immediate relief is required in acute situations. The general purpose of Hyoscine Butylbromide is to halt the excessive, painful tightening of the smooth muscle that results in cramping.

As a single-ingredient product, its therapeutic benefit is exclusively derived from its ability to relax these involuntary muscles. By interrupting the nerve signals mediated by acetylcholine, it directly addresses the cause of functional pain associated with muscle contraction. It acts to relax the spasmodic contractions within the digestive system and urinary tract. This means the drug provides a foundational spasmolytic effect, which is the easing of discomfort in the abdomen and related areas by calming the overactive muscles.

What side effects are possible with Busopin?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of Busopin (Hyoscine Butylbromide) as classified by government regulatory authorities.

Frequency-Classified Adverse Reactions

The medication’s safety profile is formally organized by the frequency of adverse reactions observed in clinical use and post-marketing surveillance. Officially classified side effects that occur as uncommon include dry mouth, tachycardia (increased heart rate), and various skin reactions such as rash and urticaria. Rare documented effects include urinary retention. Other serious reactions, such as an increase in intraocular pressure and mydriasis (pupil dilation), are officially classified with a Not Known frequency, meaning they have been reported in post-marketing experience but their precise rate cannot be estimated from clinical trial data.

Serious Adverse Reactions and Safety Constraints

Serious adverse reactions are officially documented within the regulatory framework. These include severe anaphylactic shock and clinically significant hypotension or severe tachycardia. These events are noted as particular safety concerns following administration by injection, especially in patients with pre-existing cardiac conditions (e.g., heart failure or coronary heart disease).

The label also defines specific constraints where the medication must not be used (contraindications). These include narrow angle glaucoma, myasthenia gravis, and obstructive conditions of the gastrointestinal or urinary tracts, such as paralytic ileus. Use during pregnancy and lactation is generally not recommended due to limited official data.


Regulatory Summary: The official safety profile is defined by these frequency classifications and specific constraints. This structure allows the identification of expected uncommon anticholinergic effects and highlights the serious but less frequent risks, such as severe cardiovascular events and anaphylaxis, particularly when administered parenterally.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Buspirone overdose focuses on the identification of specific clinical manifestations and mandated emergency actions. Overdosage usually results in complete recovery, even when high doses are involved, as reported in clinical trials.

Documented Manifestations and Emergency Action

Domain Official Regulatory Statement
Documented Manifestations Severe drowsiness, dizziness, nausea, vomiting, and miosis (small pupils) are the documented presentations. Loss of consciousness may occur in severe cases.
Immediate Action Required Get emergency help at once or contact a Poison Control center immediately upon suspicion of overdosage.

Overdose Management and Considerations

Regulatory documents mandate that treatment consists of general symptomatic and supportive measures. No specific antidote is known to reverse the effects of Buspirone. Procedural steps may include continuous monitoring of respiration, pulse, and blood pressure, and, where necessary, immediate gastric lavage or use of activated charcoal.

Patients with severe renal impairment or severe hepatic impairment are noted to have significantly increased exposure to the drug, which increases the potential for adverse effects in an overdose scenario.

Therapeutic Uses of Busopin

Quick Facts: Uses of Busopin

  • Relieves Symptoms: May help alleviate the symptoms associated with anxiety.
  • Management: Used for the therapeutic management of generalized anxiety disorder (GAD).
  • Short-Term Relief: Approved for the temporary reduction of anxiety symptoms.

Busopin (Buspirone) is a prescribed medication utilized in a patient's overall treatment plan to address anxiety. The primary, approved use of this drug is for the management of generalized anxiety disorder (GAD). The medication is indicated for patients whose diagnosis aligns with GAD. It may help patients with GAD feel more relaxed, support clearer thinking, and assist in the reduction of persistent worry.

Additionally, Busopin may be used for the short-term relief of anxiety symptoms. It may also be considered as an augmentation agent for unipolar depression when used alongside other established treatments, a use that falls outside of the main approved indications. It is important to note that this drug is typically not intended for anxiety or tension arising from the common stresses of everyday life.

Regulatory References

  1. NIH DailyMed guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Busopin? — Official Regulatory Information

The eligibility to use Busopin (Buspirone) is defined by official regulatory documentation and is based on a patient's age, physiological status, and concurrent medication use.

Category Official Regulatory Statement
Populations for whom use is allowed Adults (18 and older). Older adults are permitted; studies have not demonstrated age-specific problems that limit its usefulness.
Populations for whom use is not recommended Pediatric population (under 18 years) as long-term safety and effectiveness have not been established. Patients with severe renal or hepatic insufficiency.
Populations for whom use is contraindicated Patients with a known hypersensitivity or those currently taking a Monoamine Oxidase Inhibitor (MAOI), or within 14 days of discontinuing an MAOI. Contraindications also apply to patients with epilepsy or in a state of acute intoxication.
Condition-specific eligibility rules Use with caution is required for patients with mild to moderate renal or hepatic impairment. Contraindicated in certain cases of hereditary metabolic issues or severe organ dysfunction.
Pregnancy and lactation eligibility status Pregnancy: Contraindicated by some regulators or advised for use only if clearly needed due to unestablished human safety data. Lactation: Not recommended or should be avoided due to unknown levels of excretion in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Buspirone documents specific interaction patterns that may alter drug exposure or produce pharmacodynamic effects.

Contraindicated and Restricted Combinations

Classification Interacting Substance/Class Official Constraint
Contraindicated Monoamine Oxidase Inhibitors (MAOI) Co-administration is not recommended due to the potential for elevated blood pressure.
Restricted Nefazodone Regulatory review suggested contraindication due to the risk of excessively high buspirone exposure.

Pharmacokinetic and Pharmacodynamic Effects

Buspirone is metabolized primarily by the Cytochrome P450 3A4 (CYP3A4) enzyme. Strong CYP3A4 inhibitors (such as Itraconazole or Erythromycin) are documented to substantially increase buspirone plasma concentrations (AUC and Cmax). Conversely, CYP3A4 inducers (such as Rifampin) are documented to reduce buspirone exposure.

Co-administration with other serotonergic agents (including Tryptophan and Triptans) increases the official pharmacodynamic risk of Serotonin Syndrome.

Interactions with Food and Substances

Substance Interaction Type Documented Effect
Grapefruit Juice Pharmacokinetic (Inhibition) Consumption is advised against as it increases buspirone exposure and side effects.
Alcohol (Ethanol) Pharmacodynamic Avoidance is advised due to the increased risk of CNS side effects, such as dizziness.

For consistent drug exposure, the regulatory label specifies that buspirone must be taken consistently with food or consistently without food.

Mechanism of Action

Busopin, which is buspirone hydrochloride, is an azapirone compound that modulates central nervous system signaling, primarily through interaction with serotonin receptors and, to a lesser extent, dopamine receptors.

Its key biological target is the serotonin 5-HT1A receptor. Buspirone acts as a full agonist at the presynaptic 5-HT1A autoreceptors located on serotonergic neurons in the dorsal raphe, which initially hyperpolarizes the neuron and reduces its firing rate, causing a transient decrease in serotonin release. Conversely, it functions as a partial agonist at the postsynaptic 5-HT1A receptors in forebrain regions like the hippocampus and cortex.

Through chronic administration, the presynaptic 5-HT1A autoreceptors are thought to desensitize, which subsequently leads to a restoration and eventual increase in serotonergic tone in the projection areas. Furthermore, buspirone exhibits weak antagonistic activity at dopamine D2 receptors, and its major active metabolite, 1-pyrimidinylpiperazine (1-PP), acts as an antagonist at alpha2-adrenergic receptors. The collective neurochemical modulations ultimately result in systemic physiological changes involving the limbic and cortical circuits that regulate emotional processing and arousal.

Dosage and Administration Information

Official Administration Guidelines

Buspirone (Busopin) is administered exclusively through the oral route using tablets, which are available in multiple strengths to facilitate precise dosing. The official use instructions require a structured, gradual adjustment schedule.


Administration Scope

Feature Guideline
Route Oral (by mouth)
Dosing Schedule Therapy begins with a starting dose of 15 mg daily, typically divided into two doses. The dose may be adjusted by 5 mg per day increments every 2 to 3 days, up to a maximum recommended dose of 60 mg per day.
Timing with Food Doses must be taken consistently—always with food or always without food—to maintain predictable absorption levels. Patients must avoid grapefruit and grapefruit juice.
Preparation Tablets are often scored to allow for accurate division, which assists in following the required titration schedule.
Missed Dose If a dose is missed, patients should skip it and resume the schedule at the next designated time; a double dose must not be taken.

Population and Duration Constraints

  • Hepatic/Renal Impairment: Buspirone is generally not recommended for use in patients with severe kidney or liver impairment, and caution is necessary in moderate cases.
  • Older Adults: Pharmacokinetic data do not currently support specific dose changes based solely on age.
  • Course Duration: The need for continued treatment must be periodically reassessed by a healthcare professional.

Procedural Structure

The official use protocol is defined by the requirement for a slow, incremental titration of the dosage, administered in divided daily doses. This regimen is fundamentally linked to maintaining consistent intake conditions (the same relation to meals) to ensure drug levels remain stable throughout the course of use.

Recent Clinical Evidence

Research evidence / Overview of Studies for Busopin

Evidence for Use in Generalized Anxiety Disorder (GAD)

Research examined Busopin's role in the management of Generalized Anxiety Disorder (GAD), a condition characterized by fluctuating or episodic manifestations of excessive worry and tension. Research primarily examined the drug using short-term Randomized Controlled Trials (RCTs), some of which were observed in comparison to placebo, in adult outpatients who met the clinical criteria for GAD.

Researchers monitored changes in anxiety symptom severity using established tools, such as the Hamilton Rating Scale for Anxiety (HAM-A). Studies reported that symptom change was often measured after an observation period of two to four weeks, where patterns of change in anxiety symptoms were observed. The findings describe patterns observed in the studies and reported on the evolution of symptoms like persistent worry and motor tension.


Research into Busopin as an Augmentation Agent in Depression

Busopin was evaluated in studies exploring its role as an augmentation agent in depression. This research explored the role of the drug as an adjunctive option. Studies monitored measurements on depressive symptom severity scales during the period when Busopin was observed in patients also receiving an antidepressant.

While some findings describe patterns observed in the studies during the period Busopin was added to existing treatment, the findings were mixed in comparisons that included a placebo group within the overall study population. The data show patterns related to symptom evolution primarily in certain subgroups of patients, particularly those who began the trial with more intense depressive symptoms.


What is Still Uncertain About the Research Evidence

The available evidence highlights several areas where research is ongoing or where data remain insufficient. A key area of uncertainty is the duration of effect, as controlled trials have not established the sustained pattern of the drug beyond the first several weeks. Long-term effects are not fully established, and comparative evidence is lacking in some areas, making it difficult to fully contextualize the findings.

Furthermore, the data for certain groups remain insufficient. The research base is limited for populations outside of the general adult demographic, such as children and adolescents, with available studies typically being small-scale pilot studies. Study results reflect the specific conditions under which they were conducted, and evidence highlights what is known — and what is still uncertain.

Key Studies & References

  1. Buspirone Hydrochloride Tablet, Official Drug Label and Information
  2. National Institute for Health and Care Excellence (NICE) Clinical Guideline: Generalized anxiety disorder and panic disorder in adults

Frequently Asked Questions (FAQ)

Common questions about Busopin (FAQ)

Q: How quickly can I expect Busopin to start working?

Official studies indicate that Busopin does not provide immediate relief from anxiety. The full clinical effect is typically observed after approximately two to four weeks of continuous use in controlled trials.


Q: Is Busopin safe to take for long periods?

Official product information states that the effectiveness of Busopin has not been established in long-term studies lasting more than three to four weeks. Official guidance indicates the need for continued treatment is subject to periodic reassessment.


Q: Why do some people say Busopin takes a long time to show results?

The mechanism of action for Busopin is related to chronic changes in certain serotonin receptors in the brain, rather than a rapid effect. This gradual adjustment in brain chemistry is a characteristic that differs from some medications with rapid onset.


Q: Can Busopin affect my ability to drive or operate machinery?

Official warnings advise caution when operating machinery or driving due to the potential for side effects such as dizziness or drowsiness. This is due to its classification as a central nervous system (CNS) active drug.


Q: Are there studies showing how Busopin affects the long-term well-being of patients?

Controlled trials have focused primarily on short-term outcomes and have not systematically established the sustained pattern of effect beyond the first several weeks. Therefore, official regulatory sources note that the long-term effects of Busopin are not fully established.


Q: What is the average duration of treatment with Busopin?

Regulatory documents indicate that the appropriate duration of treatment for generalized anxiety disorder (GAD) has not been systematically defined in controlled trials. Official guidance indicates the need for continued use is subject to periodic evaluation by a healthcare professional.


Q: What are the most commonly reported side effects of Busopin?

According to the official adverse reaction reports, the most frequently observed side effects, reported at a rate higher than in the placebo groups, include dizziness, nausea, headache, excitement, and nervousness.


Q: What are the most critical side effects or signs I should watch out for?

Official documentation lists serious but infrequent adverse reactions, including symptoms associated with Serotonin Syndrome (agitation, rapid heartbeat, severe muscle stiffness). Other serious reactions include unusual, uncontrolled movements.


Q: Is Busopin considered an antidepressant?

No. Official product information states that Busopin is indicated for the management of anxiety disorders and is classified as an antianxiety agent. Its approved therapeutic purpose is not as a primary treatment for depression.


Q: Is Busopin the same as a benzodiazepine or a controlled substance?

Busopin is a unique anxiolytic agent that is not chemically or pharmacologically related to the benzodiazepines. Furthermore, official regulatory bodies state that Busopin is not currently scheduled as a controlled substance.


Q: What is the main difference between Busopin and other common medications for similar conditions?

Busopin is distinctive because it is an anxiolytic that does not exhibit the prominent sedative, anticonvulsant, or muscle relaxant effects associated with benzodiazepines. It works through a different mechanism, primarily targeting serotonin receptors.


Q: Will Busopin cause weight gain?

Official reports on adverse reactions state that both weight gain and weight loss have been reported as infrequent events in clinical trials. Neither change is listed as a commonly reported side effect of the medication.


Q: Can Busopin make me feel drowsy or tired?

Yes, official regulatory information lists both drowsiness and tiredness as commonly reported side effects of the medication. This is listed as a central nervous system (CNS) effect.


Q: Is it possible to become dependent on Busopin?

Official information indicates that Busopin is not associated with significant physical dependence or the kind of severe withdrawal symptoms typical of benzodiazepine drugs. It does not exhibit cross-tolerance with that drug class.


Q: Why is Busopin sometimes described as 'non-addictive'?

Busopin is described as non-addictive because it is designed to work differently than medications with known abuse potential. Regulatory information confirms that it does not interact with the specific brain receptors associated with the dependence seen with benzodiazepines.


Q: Can Busopin be taken with pain relievers like ibuprofen or acetaminophen?

The official label does not specifically list interactions with common pain relievers such as ibuprofen or acetaminophen. However, regulatory information indicates caution when taken alongside other central nervous system (CNS) active drugs.


Q: Does Busopin affect sleep quality?

Yes, official adverse reaction reports list side effects that can affect sleep. These commonly reported effects include experiencing difficulty falling asleep or staying asleep (insomnia), as well as having abnormal dreams.


Q: Is Busopin known to interact with herbal supplements?

Official sources note that Busopin is metabolized by an enzyme called CYP3A4. Certain herbal supplements that affect this enzyme could alter drug levels. Caution is also noted for any supplements classified as serotonergic agents.


Q: Are there common withdrawal symptoms associated with stopping Busopin?

Official regulatory documents indicate that Busopin itself is not associated with a recognized withdrawal syndrome typical of benzodiazepines. However, if a person is transitioning from another CNS-depressant drug, Busopin will not prevent withdrawal symptoms from that prior medication.


Q: Is it true that Busopin works differently than most anxiety medications?

Yes, this is accurate. Busopin is an anxiolytic that is not chemically related to the benzodiazepines or other common sedative medications. It is described as acting primarily through its effect on specific serotonin receptors in the brain.


Q: Can Busopin cause changes in mood or personality?

Official safety data lists adverse reactions that are related to central nervous system effects. These reported side effects include feelings of anger or hostility, excitement, and nervousness, which are noted as potential effects on mood or behavior.


Q: What if Busopin doesn't seem to be working for me after a few weeks?

The full clinical effect may take two to four weeks to manifest. Official guidelines allow for adjustment of the daily amount, administered in small increments, up to the maximum recommended daily dose.


Q: Can Busopin cause problems with sexual function?

Official adverse reaction reports have included infrequent events related to sexual function. These reported reactions include both a decreased or increased libido, as well as delayed ejaculation and impotence.


Q: Is Busopin generally considered non-sedating?

Studies indicate that Busopin is less sedating than other anxiolytics commonly used for anxiety. The drug lacks the prominent sedative effect that is strongly associated with certain other classes of antianxiety medications.


Q: What does the term 'non-benzodiazepine anxiolytic' mean in relation to Busopin?

This term is used to describe antianxiety medications that are not chemically part of the benzodiazepine class of drugs. This classification is important because it means Busopin does not produce the same sedative, hypnotic, or muscle-relaxant effects.


Q: Can Busopin affect blood sugar levels?

The official label does not directly list an effect on blood sugar levels. However, it advises caution for patients who have pre-existing conditions like metabolic acidosis, which can be associated with uncontrolled blood sugar issues.


Q: How is Busopin eliminated from the body?

Busopin is processed primarily by the CYP3A4 enzyme in the liver. Official pharmacokinetic data shows that the final elimination of the drug from the body occurs mainly through the urine and to a lesser extent through the feces.


Q: What does 'selective serotonin reuptake inhibitor (SSRI)' mean, and is Busopin one?

Busopin is not an SSRI. It belongs to a different chemical class (azapirone) and works by acting directly on certain serotonin 5-HT1A receptors. This mechanism is distinct from the reuptake inhibition action of SSRIs.


Q: Can I take Busopin if I have high blood pressure?

The label notes that concurrent use with MAOIs is prohibited due to the risk of elevated blood pressure. Furthermore, regulatory documents list that changes in blood pressure (both increases and decreases) are a rare side effect.


Q: Does Busopin require lab tests or monitoring while taking it?

Official documents note that Busopin may interfere with a specific laboratory test used to screen for pheochromocytoma (a condition of the adrenal glands). This interference can potentially lead to a false positive result.


Q: Are there any known interactions between Busopin and common cold or flu medicines?

Regulatory documents list that caution is required with cold and flu medications that contain sympathomimetic agents (like certain decongestants) due to the risk of cardiovascular side effects. Caution is also noted for products containing agents like dextromethorphan due to the risk of Serotonin Syndrome.


Q: Why is Busopin not used for acute or panic attacks?

Official indications state the drug is approved for the management of chronic anxiety, not the short-term or acute relief of anxiety symptoms. The drug is not immediate-acting, which is required to treat acute panic or anxiety attacks effectively.


Q: Does Busopin interact with common heart medications?

Yes, official drug interaction data indicates that Busopin interacts with medications that inhibit the CYP3A4 enzyme, which includes some common heart medications. For example, drugs such as diltiazem and verapamil can significantly increase the levels of Busopin in the body.


Q: Can people with a history of substance use disorders take Busopin?

The official label notes that Busopin is not associated with the dependence or abuse potential of the benzodiazepine class of drugs. However, the label does not provide specific eligibility guidance for people with a history of substance use disorders.


Q: Is Busopin available as a generic medication?

Yes, the regulatory body (FDA) has determined that the original brand drug was not withdrawn for safety or effectiveness reasons. This decision allows for the approval and sale of generic versions of the medication.


Q: How does Busopin's action differ from a traditional sedative?

Busopin is not chemically related to traditional sedatives like benzodiazepines. Official information highlights that it lacks the prominent hypnotic, muscle-relaxant, and overall sedative effects that are usually associated with those drugs.

How should Busopin be stored and disposed of?

Storage and Disposal of Busopin (Buspirone)

Storage Requirements

Busopin tablets must be stored at controlled room temperature, generally defined as 25 C (77 F), with permissible excursions between 15 C and 30 C (59 F and 86 F). The medication must be kept away from light, moisture, and excess heat.

It is required that the product remain in a tight, light-resistant container and that the container be kept tightly closed when not in use. As a mandatory safety measure, the medicine must be stored out of the sight and reach of children.

Disposal Instructions

Official regulatory guidance specifies that unused or expired Busopin tablets should not be flushed down the toilet. The preferred disposal methods are utilizing a drug take-back program or a mail-back envelope. If these are unavailable, the medicine may be mixed with an unappealing substance, placed in a sealed bag, and discarded with household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Busopin found in:

A-Z Index: